Skip to content

Cellular Immune Responses in Triple-negative Breast Cancer - High Throughput Immunogenetic Studies

Cellular Immune Responses in Triple-negative Breast Cancer - High Throughput Immunogenetic Studies

Status
Enrolling by invitation
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06646263
Enrollment
150
Registered
2024-10-17
Start date
2024-03-01
Completion date
2028-04-30
Last updated
2024-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Triple Negative Breast Cancer

Keywords

T cells, Tumor-infiltrating lymphocytes, Next-generation sequencing, T cell receptor, Spatial transcriptomics, Neoepitopes, TR beta chain, TRb clonotypes, TRb gene repertoire, Cellular immunity

Brief summary

This project introduces a novel methodology for the in-depth immunogenetic characterization of the TR gene repertoire in solid tumors, holding the promise to offer unprecedented insights into the TR anti-tumor specificity and the prognostic/predictive value of TR gene repertoire signatures.

Detailed description

The goal of this observational study is to address the role of T cells in the tumor microenvironment of TNBC. In detail, this study aims to: (i) explore the immunogenetic characteristics of the TR gene repertoire as informative prognostic/predictive biomarkers in TNBC (ii) identify immunogenic neoepitopes arising from common tumor-specific non-synonymous gene mutations, as well as the corresponding neoepitope-specific T cells (iii) describe, in single-cell resolution, the spatial organization of the intricate crosstalk between tumor cells and neoepitope specific-T cells, and (iv) delineate the functional properties of T cells within the TME. All the experimental results, regarding the TR repertoire features and the spatial organization of the TME, will be correlated with clinical outcome measurements (e.g. overall survival, progression time), which are available from the detailed patients medical record.

Interventions

None listed

Sponsors

Hellenic Cooperative Oncology Group
CollaboratorOTHER
Institute of Applied Biosciences
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Healthy volunteers
No

Inclusion criteria

\- Confirmed TNBC diagnosis

Exclusion criteria

\-

Design outcomes

Primary

MeasureTime frame
T cell receptor profiling as a potential biomarker in Triple-Negative Breast Cancer4 years

Countries

Greece

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026